There are currently 90 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
NCT04368039
Recruiting
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Gender:
ALL
Ages:
Between 15 years and 35 years
Trial Updated:
10/28/2024
Locations: Harding Hospital, Columbus, Ohio
Conditions: Psychosis, Schizophrenia, First-episode Psychosis
Register for Updates
CAE for Poorly Adherent Individuals with Schizophrenia
NCT06061952
Recruiting
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Schizophrenia
Register for Updates
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
NCT00001246
Recruiting
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution. Functional MRIs are diagnostic tests that allow doctors to not only view anatomy, but physiology and function. It is for these reasons that MRIs are excellent methods for studying the brain. In this study, researchers will use MRI to assess brain anatomy and function in X and Y chromosome variation... Read More
Gender:
ALL
Ages:
Between 3 years and 120 years
Trial Updated:
05/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/01/2025
Locations: Alea Research, Phoenix, Arizona +172 locations
Conditions: Schizophrenia
Register for Updates
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCT06315283
Recruiting
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with ora... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/01/2025
Locations: Teva Investigational Site 15739, Los Alamitos, California +8 locations
Conditions: Schizophrenia
Register for Updates
Remote State Representation in Early Psychosis
NCT05538832
Recruiting
The purpose of this study is to examine state representation in individuals aged 18-30 who have been diagnosed with a psychotic illness, as well as young adults who do not have a psychiatric diagnosis. State Representation is our ability to process information about our surroundings. The investigators will complete some observational tests as well as a cognitive training clinical trial.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/29/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Psychosis, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders, Psychotic Disorders, Psychotic Mood Disorders, Psychoses, Affective, Psychosis Nos/Other, Schizophrenia Spectrum and Other Psychotic Disorders
Register for Updates
State Representation in Early Psychosis
NCT05273164
Recruiting
The purpose of this study is to examine state representation in individuals aged 15-45 who have been diagnosed with a psychotic illness, as well as young adults who do not have a psychiatric diagnosis. State Representation is our ability to process information about our surroundings. The investigators will complete some observational tests as well as a cognitive training clinical trial.
Gender:
ALL
Ages:
Between 15 years and 45 years
Trial Updated:
04/28/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
Register for Updates
State Representation in Early Psychosis - Project 4
NCT05664594
Recruiting
The purpose of this study is to examine state representation in individuals aged 15-45 who have been diagnosed with a psychotic illness, as well as young adults who do not have a psychiatric diagnosis. State Representation is our ability to process information about our surroundings. The investigators will complete a clinical trial examining two paradigms of cognitive training.
Gender:
ALL
Ages:
Between 15 years and 45 years
Trial Updated:
04/28/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Psychosis, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizoaffective Disorder
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Sun Valley Behavioral Med Center, Imperial, California +19 locations
Conditions: Schizophrenia
Register for Updates
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964
Recruiting
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
04/23/2025
Locations: Site 5038, Garden Grove, California +5 locations
Conditions: Schizophrenia, Cognitive Impairment
Register for Updates
Neuronal Effects of Exercise in Schizophrenia
NCT02455193
Recruiting
This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and the brain's response to food. In this study, the investigators will be evaluating how participants' brains respond to food images as well as asking questions about their food preferences and intake and clinical symptoms. The investigators may also ask participants to complete an exercise or diet intervention to see how... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
04/21/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Schizophrenia
Register for Updates
Study of SPG302 in Adults With Schizophrenia
NCT06442462
Recruiting
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/17/2025
Locations: CenExel CNS, Garden Grove, California +2 locations
Conditions: Schizophrenia
Register for Updates